Journals / Acta Orthopaedica et Traumatologica Turcica / 2006 / Cilt: 40 - Sayı: 5

An analysis of genetic transmission in a father and son with osteosarcoma

Osteosarkomlu baba ve oğulda genetik geçişin irdelenmesi

Pages
407–410
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Genetic abnormalities documented in the father and son corroborate the presence of specific genetic alterations in the pathogenesis of osteosarcoma.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Familial osteosarcoma is a rare hereditary disease.
📊
Key Findings & Data:We present a 37-year-old father and a 17-year-old son who developed osteosarcoma in the left and right distal femurs, respectively, at a three-year interval.
💡
Conclusion & Impact:Genetic abnormalities documented in the father and son corroborate the presence of specific genetic alterations in the pathogenesis of osteosarcoma.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Genler · p53 · Kemik neoplazmları

Abstract

Familial osteosarcoma is a rare hereditary disease. We present a 37-year-old father and a 17-year-old son who developed osteosarcoma in the left and right distal femurs, respectively, at a three-year interval. They were treated with chemotherapy followed by surgery. Both had positive immunostaining for p53 tumor suppressor gene and HER-2/neu oncogene. The son also exhibited deletion of the retinoblastoma 1 gene. Pulmonary metastasis was detected in the father at the time of diagnosis and 13 months after primary treatment, whereas no distant metastasis was present in the child. The father died 39 months after the diagnosis from primary symptoms, but the son led a disease-free survival a year after completion of treatment. Genetic abnormalities documented in the father and son corroborate the presence of specific genetic alterations in the pathogenesis of osteosarcoma.

Özet

Ailesel osteosarkom kalıtımsal sendromlar içinde nadir görülen bir hastalıktır. Otuz yedi yaşında bir babada ve, babaya tanı konmasından üç yıl sonra, 17 yaşındaki oğlunda sırasıyla sol ve sağ femur distalinde osteosarkom saptandı. İki olguya da kemoterapi ve cerrahi tedavi uygulandı. Her iki olguda da p53 tümör baskılayıcı gen ve HER-2/neu onkogeni immünhistokimyasal olarak pozitif bulundu. Ek olarak, çocukta retinoblastom 1 gen kaybı vardı. Babada tanı anında ve tedaviden 13 ay sonra akciğer metastazı saptandı. Çocukta uzak metastaz yoktu. İlk olgu, gelişen merkezi semptomlara bağlı olarak tanıdan 39 ay sonra kaybedilirken, oğul tedavinin tamamlanmasından sonraki birinci yılda hastalıksız olarak yaşamını sürdürmekteydi. Her iki olguda belirlenen genetik anormallikler osteosarkomun patogenezinde spesifik genetik değişikliklerin rol oynayabileceğini desteklemektedir.

🔖

Cite This Article

TOKATLI, F., ALAS, C. R., ALTANER, Ş., PALA, F., UYGUN, K., UZAL, M. C., YALNIZ, E. (2006). An analysis of genetic transmission in a father and son with osteosarcoma. Acta Orthopaedica et Traumatologica Turcica, Cilt: 40 - Sayı: 5, 407–410. https://ajindex.com/articles/354480

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15
  2. Akatsuka T, Wada T, Kokai Y, Sawada N, Yamawaki S, Ishii S. Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma. Oncology 2001;60:361-6
  3. Onda M, Matsuda S, Higaki S, Iijima T, Fukushima J, Yokokura A, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 1996;77: 71-8
  4. Ozaki T, Ikeda S, Kawai A, Inoue H, Oda T. Alterations of retinoblastoma susceptible gene accompanied by c-myc amplification in human bone and soft tissue tumors. Cell Mol Biol 1993;39:235-42
  5. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y, et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 1994;54:3042-8
  6. Goto A, Kanda H, Ishikawa Y, Matsumoto S, Kawaguchi N, Machinami R, et al. Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas. Jpn J Cancer Res 1998;89:539-47
  7. Hillmann A, Ozaki T, Winkelmann W. Familial occurrence of osteosarcoma. A case report and review of the literature. J Cancer Res Clin Oncol 2000;126:497-502
  8. Chin KR, Mankin HJ, Gebhardt MC. Primary osteosarcoma of the distal femur in two consecutive brothers. Clin Orthop Relat Res 2001;(382):191-6
  9. Longhi A, Benassi MS, Molendini L, Macchiagodena M, Picci P, Bacci G. Osteosarcoma in blood relatives. Oncol Rep 2001;8:131-6
  10. Toguchida J, Ishizaki K, Sasaki MS, Nakamura Y, Ikenaga M, Kato M, et al. Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma. Nature 1989;338:156-8
  11. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307-25
  12. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8
  13. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992;326:1301-8
  14. Kilpatrick SE, Geisinger KR, King TS, Sciarrotta J, Ward WG, Gold SH, et al. Clinicopathologic analysis of HER- 2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod P